Thank you, Chair. Thank you, witnesses.
Mr. Keon, very quickly to you.
It would appear that you have a very significant, involved, cumbersome process by which you get applications, by which you have to negotiate with the brand-name holder, understandably. Except for the provision you referred to as far as ensuring there is absolute certainty and approval from Health Canada, you've suggested you would support the legislation. I'm wondering if you could give us an example specifically of where quantity and time may have a lot to do with the fact that no generic would dare try to reproduce what happened in Rwanda.